About Bio-Techne
Bio-Techne is a company based in Minneapolis (United States) founded in 1981 was acquired by Merck in June 2026. The company has 3,100 employees as of June 30, 2025. Bio-Techne has completed 18 acquisitions, including ACD Bio, Asuragen and Atlanta Biologicals. Bio-Techne offers products and services including Reagents and Kits, Analytical Instruments, and ELISA Kits. Bio-Techne operates in a competitive market with competitors including Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.
- Headquarter Minneapolis, United States
- Employees 3100 as on 30 Jun, 2025
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bio-Techne Corp
-
Annual Revenue
$1.22 B (USD)5.23as on Jun 30, 2025
-
Net Profit
$73.36 M (USD)-56.35as on Jun 30, 2025
-
EBITDA
$362.84 M (USD)-6.18as on Jun 30, 2025
-
Latest Funding Round
$153 K (USD), Grant
Jun 01, 2016
-
Investors
Merck
& 1 more
-
Employee Count
3100
as on Jun 30, 2025
-
Investments & Acquisitions
ACD Bio
& 17 more
-
Acquired by
Merck
(Jun 25, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bio-Techne
Bio-Techne is a publicly listed company on the NASDAQ with ticker symbol TECH in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bio-Techne
Bio-Techne offers a comprehensive portfolio of products and services, including Reagents and Kits, Analytical Instruments, and ELISA Kits.
High-quality reagents for cell culture, assays, and protein analysis in scientific research.
Tools for immunoassays, protein analysis, and diagnostics in life sciences applications.
Kits for detecting and quantifying proteins in research and diagnostic settings.
People of Bio-Techne
Unlock access to complete
Software Development Team
92 people
Sales and Marketing
76 people
Leadership Team
40 people
Product Management Team
35 people
Senior Team
31 people
Finance and Accounting
20 people
Human Resources and Administration
18 people
Advanced Team
13 people
Unlock access to complete
Funding Insights of Bio-Techne
Investors in Bio-Techne
Bio-Techne has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Merck and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Merck is engaged in science and technology solutions globally.
|
Locked | Locked | Locked |
Investor details for Bio-Techne
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bio-Techne
Bio-Techne has strategically engaged in corporate development activities, having acquired 18 companies. Notable acquisitions include ACD Bio, Asuragen and Atlanta Biologicals.
Investment portfolio details for Bio-Techne
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer of solutions for gene editing and gene delivery
|
Locked | Locked | 2015 | Locked | |
|
Microfluidic-based instruments for tumor analysis are developed.
|
Locked | Locked | 2014 | Locked | |
|
Single-cell sorting instruments are developed using microfluidic technology.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for Bio-Techne
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Bio-Techne
Detailed financials for Bio-Techne
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bio-Techne Comparisons
Peer comparison for Bio-Techne
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bio-Techne
Bio-Techne operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Portfolio of products and services for life science research and clinical diagnostic markets
|
|
| Locked | Locked | Locked |
AI-based medical diagnostics are developed for healthcare applications.
|
|
| Locked | Locked | Locked |
Merck is engaged in science and technology solutions globally.
|
|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Primary antibodies and instruments for immunohistochemistry are manufactured.
|
|
| Locked | Locked | Locked |
Tissue hypothermic storage and cryopreservation freeze media are developed.
|
Detailed competitors of Bio-Techne
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bio-Techne
Complete news archive for Bio-Techne
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bio-Techne
Bio-Techne was founded in 1981 and raised its 1st funding round 28 years after it was founded.
Bio-Techne is headquartered in Minneapolis, United States. It is registered at Minneapolis, Minnesota, United States.
As of Jun 30, 2025, the latest employee count at Bio-Techne is 3,100.
Annual revenue of Bio-Techne is $1.22B as on Jun 30, 2025.
Bio-Techne was founded in 1981 in Minneapolis, United States, within the biotechnology sector. Specialized proteins such as cytokines and growth factors are supplied, alongside antibodies, immunoassays, biologically active small molecules, and other reagents to research, diagnostics, and clinical control markets. Instrumentation is provided to streamline protein analysis processes for customers in these areas. Operations focus on supporting scientific and medical applications across the United States and internationally.
Bio-Techne's top competitors include Biocare Medical, Merck and Siemens Healthineers.
Bio-Techne offers Reagents and Kits, Analytical Instruments, and ELISA Kits.
Yes, Bio-Techne is publicly traded on NASDAQ under the ticker symbol TECH.
Bio-Techne has made 18 acquisitions, including ACD Bio, Asuragen, and Atlanta Biologicals.
The ticker symbol of Bio-Techne is TECH on NASDAQ.